Abstract:The bovine spongiform encephalopathy (BSE) epidemic, along with the related threat to human health posed by the transmission of the BSE agent to humans, has highlighted the importance of prion diseases. These fatal neurodegenerative diseases are characterised by spongiform changes in the CNS, and comprise a wide spectrum of clinicopathological entities in humans and animals, such as Creutzfeldt-Jakob disease (CJD) and its emerging new variant (vCJD) in humans, and BSE and scrapie in animals. This article reviews the geographical distribution and the temporal trends of CJD and vCJD; the major events in the pathogenesis of prion diseases; the risk factors for sporadic CJD and vCJD; and the possible strategies for treating them. Worldwide statistics indicate that sporadic CJD has a stable incidence of one case per million people per year; in contrast, the incidence of vCJD appears to have increased exponentially from its characterisation in 1994 to a peak in 2000. As of December 2005, 183 definite or probable cases of vCJD had been reported worldwide. The crucial event in the pathogenesis of prion diseases is the conversion of the normally occurring cellular prion protein (PrP(c)) into a pathogenic form, called protease-resistant PrP (PrP(res)) or scrapie PrP (PrP(sc)). Pathogenetic studies in rodent models have shown that PrP(sc) is found in the enteric nervous system and in the gut-associated lymphoid tissue following oral scrapie ingestion. The role of the lymphoreticular system in the pathogenesis of TSE seems to be related to the strains of agents and the host genotype. Therapeutic approaches to vCJD are mainly based on the inhibition or prevention of the pathological change that creates PrP(sc). Derivatives of acridine (such as mepacrine [quinacrine]) and the phenothiazine psychotropics have been proposed as possible therapies because of their activity in cellular models; however, neither class was able to affect the protease resistance of preexisting PrP fibrils. More encouragingly, in animal models of prion disease, tetracyclines were found to reduce prion infectivity by direct inactivation of PrP(sc). While these findings are promising, the suitability of these compounds for clinical use is still limited by their low efficacy once symptoms are apparent. Treatments based on the vaccination approach have also produced positive results, but further investigations are necessary to establish their clinical application.

Detection and control of prion diseases in food animals

Prion diseases: current understanding of epidemiology and pathogenesis, and therapeutic advances

Progress and Problems in the Diagnostics of Transmissible Spongiform Encephalopathy

The Zoonotic Potential of Chronic Wasting Disease-A Review

Atypical transmissible spongiform encephalopathies in ruminants: a challenge for disease surveillance and control

Conventional and State-of-the-Art Detection Methods of Bovine Spongiform Encephalopathy (BSE)

Bovine spongiform encephalopathy: a tipping point in One Health and Food Safety

Prions, BSE and food

Progress on Low Susceptibility Mechanisms of Transmissible Spongiform Encephalopathies.

PrP(Sc) of Scrapie 263K Propagates Efficiently in Spleen and Muscle Tissues with Protein Misfolding Cyclic Amplification.

Detection of Chronic Wasting Disease Prions in Prairie Soils from Endemic Regions

Detection of prions from spiked and free-ranging carnivore feces

Vaccines for prion diseases: a realistic goal?

Research Progress of Prion Characteristics and Pathogenesis

Variant Creutzfeldt-Jakob disease: pathology, epidemiology, and public health implications

Bovine spongiform encephalopathy: a neuropathological perspective

The Overview of Methods for Detecting Prion Disease

Detection of Abnormal Prion Protein by Immunohistochemistry

The importance of ongoing international surveillance for Creutzfeldt–Jakob disease

Prion Infectivity and PrPBSE in the Peripheral and Central Nervous System of Cattle 8 Months Post Oral BSE Challenge